On-line version ISSN 1678-4227
Arq. Neuro-Psiquiatr. vol.60 no.2A São Paulo June 2002
ABSTRACT - Esthesioneuroblatoma (ENB) is a rare tumor arising from the olfactory epithelium of the nasal vault which frequently invades the cranial base, cranial vault and orbit. ENB has a bimodal age distribution between 11 and 20 years and between 51 and 60 years. ENB accounts for approximately 1 to 5% of intranasal cancers and no consensus has been reached regarding treatment of this tumor. We report on a 66 year old female patient with a Kadish stage C tumor with frontal lobe invasion submitted a total craniofacial resection with a combined head neck and neurosurgeon team. The purpose of this study is to analyze the natural history, treatment and prognosis of this tumor, based on the literature review.
KEY WORDS: esthesioneuroblastoma, craniofacial surgery, skull base surgery.
Estesioneuroblastoma: relato de caso
RESUMO - Estesioneuroblastoma é um tumor raro originado do epitélio olfactivo, frequentemente invadindo a base do crânio e a região orbitaria. É tumor que pode ser encontrado em qualquer idade mas apresentando dois picos de frequência entre 11 e 21 anos e 51 e 60 anos, raros em criança. A distribuição por sexo é praticamente igual mas com uma pequena predominância masculina. O diagnostico histopatológico é feito de forma definitiva por métodos imunohistoquímicos. A sintomatologia clínica corresponde ao de uma neoplasia intranasal ou frontobasal. Devido a raridade destes tumores não se chegou ainda a um consenso em relação ao tipo de tratamento. Relatamos o caso de uma paciente 66 anos de idade com um tumor classificado como Kadish tipo C, com invasão dos seios da face e lobo frontal, que foi submetida a ressecção crânio facial por uma equipe multidisciplinar. A historia natural o tratamento e o prognóstico dos pacientes portadores destes tumores serão analisados baseando-se numa revisão da literatura.
PALAVRAS-CHAVE: estesioneuroblastoma, cirurgia crânio facial, cirurgia da base do crânio.
Esthesioneuroblastoma (olfactory neuroblastoma) (ENB) is a rare neuroepithelial tumor that arises from the olfactory epithelium in the cribriform place or nasal cavity1. First described in 1924 by Berger2 it has a histological pattern similar to that of sympathetic ganglia, retina, and adrenal medulla2 and only recently3 became recognized as a distinct pathologic entity probably as a result of immunohistochemistry and by means of electron microscopy techniques. They have helped differentiate ENB from similar undifferentiated nasal cavity tumors3. ENB account for 1 to 5% of malignant neoplasm of the nasal cavity. Fewer than 945 cases are reported in the world literature4, and most of the reports were in small series. Unlike most other neuroectodermal tumors, which manifest in childhood, ENB, has a bimodal age distribution between 11-20 years and 51-60 years5. The symptoms are related to sites and invasion of the tumor. The staging system based on tumor extension that was presented by Kadish et al.6 in 1976 has been widely accepted. The treatment of choice is a multidisciplinary craniofacial surgical resection that has improved considerably the prognosis.
The purpose of this study is to analyze the natural history, treatment and prognosis of this tumor, based on the literature review.
A 66 years old woman with a one year history of constant bifrontal facial headache, nasal obstruction, anosmia has presenting for about two months visual blurring, lacrimatiom and ocular pain followed one week later by epistaxis. Physical examination revealed a bilateral nasal mass that was endonasal endoscopy biopsy-proven to be an ENB. CT and MRI (Fig 1) demonstrated that the tumor filled the entire nasal cavity, ethmoid sinuses, sphenoid sinus, and left frontal sinus. The tumor invaded the cribriform plate and the left frontal lobe. The patient underwent a craniofacial resection with a combined neurosurgeon and head neck surgeon team. A bicoronal incision with frontal craniotomy, and in bloc resection of the frontal tumor and frontal base with preservation the pericranial flap, that was placed along the floor of the anterior cranial fossa and sutured to the residual sphenoid bone as well as though the residual dura, combined with an extended lateral rhinotomy, with totally resection of the infra cranial tumor. In the post operatively MRI (Fig 2), no tumor was found. The patient receives 56 Gy of external beam radiotherapy over a 6-week period, and chemotherapy. She showed no recurrence after one year.
Esthesioneuroblastoma is a very rare malignancy of the neuroepithelium. It was first described by Berger et al. in 1924, as "l' esthesioneuroepitheliome olfactif"2 and was only introduced into the American literature by Schall and Lineback7 in 1951. Nearly all of the 945 cases have been reported within the last 40 years. Embryologically, the olfactory nerves develop from the olfactory placode present in the fetal olfactory mucosa8,9. Histologically, there are a number of criterias that help in its diagnosis: neuroepithelial cells arranged in the classic pseudorosette pattern; fibrillar intracellular background; marked microvascularity; and round or fusiform cells approaching the size of lymphocytes with poorly defined, almost nonexistent cytoplasm1,10,11. Correct diagnosis often requires confirmatory examination with electron microscopy for the detection of neurosecretory granules. More recently immunohistochemical methods for detection of neuronspecific enolase (NSE) and S-100 protein with negative epithelial, muscle, and lymphoid antigens allowed further confirmation of ENB1,12. This tumor must be differentiated from neoplasm of the nasal cavity and paranasal sinus, such as lymphoma, sarcoma, plasmacytoma, malignant melanoma, anaplastic carcinoma, rhabdomyosarcoma, and transitional cell carcinoma11,13.
ENB has a bimodal age distribution with an early peak from 11 to 20 years and a later peak between 51 and 60 years of age10. Our patient was a 66 years old woman. There is a slight male predominance13. The staging system based on tumor extension that was presented by Kadish et al.6 in 1976 has been widely accepted. This staging system is predictive of disease-related mortality. The system classifies patients with tumors limited to the nasal cavity as stage A. Patients with tumors involving the nasal cavity and extending into the paranasal sinuses are stage B, and stage C are tumors spreading beyond the nasal cavity and paranasal sinuses, as our patient. This system has been advocated by some, because of its simplicity and acceptable prognostic efficacy. Recently, Morita et al.14 justified a modified classification with stage D tumors, presenting metastases in cervical lymph nodes distant. Two other staging methods, the Biller method15 and the Dulguerov method16, have also been described and used.
ENB is a slow growing tumor and the patients may have a history of progressive symptomatology for months to years, our patient has a one-year evolution. The presenting symptoms are nonspecific and related to the sites and invasion of the tumor. The most common finding on physical examination was the presence of a nasal mass as our patient. Recurrent epistaxis is sometimes present. Penetration into the cribriform plate can cause anosmia. Ophthalmological symptoms as ptosis, diplopia, visual blurring, ocular pain, proptosis, and excessive lacrimatiom may be found. Ear pain and otitis can result from tumor obstructing the Eustachian tube. Frontal headache suggests involvement of the frontal sinus. Cranial nerves may also be affected inducing nerve paralysis14,17. Alteration of mental status may be present if frontal lobe is invaded.
The diagnosis and evaluation of staging of ENB can be done by CT, which provides the best information about the tumor invasion into bony structures12. The tumor is presented as a homogeneous density mass, equal to or greater than the surrounding soft tissues. There are no tumor cysts or calcifications. Contrast enhancement was usually moderate and homogeneous. Coronal images were of value in evaluating extension to the orbital and through the cribriform plate and the anterior cranial fossa12. MRI shows a tumor hypointense to gray matter on T1-weighted images and iso or hyperintense on T2-weighted images. Gadolinium enhancement was observed to some degree in all cases. Fat saturated T1-weighted spin-echo images with and without gadolinium enhancement of particular value in differentiating enhancing tumor from post-obstructive mucous debris and evaluating tumor extension to the non-enhancing orbital fat12. MRI is more accurate in depicting the exact margins of intracranial tumor extension because of its multiplanar display and superior tissue contrast12.
Metastasis occurs in about 10 to 30% of patients18,19. The most common sites for metastasis spread are the cervical lymph nodes, less frequent are lung and pleura, brain, bone, spinal column, breast, and abdominal viscera20,21. Metastasis to the central nervous system is infrequent and usually identified only at post-mortem examination5. In the spinal cord 80% of metastasis are in the cauda equine18.
Our patient underwent a combined craniofacial approach utilizing a bicoronal flap for superior exposure and a lateral rhinotomy for infracranial exposure. Reconstruction varied according to the extend of the surgical resection and resultant defect. We do not use bony reconstruction of the floor of the anterior cranial fossa and supraorbital areas, but the pericranial flap is placed along the floor of the anterior cranial fossa and sutured to the residual sphenoid bone and residual dura matter to obtaining a watertight dural seal. Fibrin glue is use to assist dural seal and to secure a watertight closure. There are great variations in treatment for ENB. Some series advocate a protocol with surgery15,19-22, radiotherapy6,10,19,23 alone, combined surgery and pre operative radiotherapy13,24, and combined surgery and postoperative radiotherapy22,25. The optimum management for ENB is probably surgery using the concept first described in 1971 by Doyle and Payton26: radical surgery with a combined craniofacial approach12 taken by craniofacial team, including neurosurgery and head neck surgery. This technique has provided enhanced exposure and the possibility to achieve gross total resection. In patients without extension of tumors to the superior nasal vault or the cribriform plate, an intracranial exploration and remove of the floor of the anterior cranial fossa must be performed. This approach has had a decrease incidence of local recurrence1. It is proved that the bone in this area may harbor tumor cells with a potential cause of recurrence. This was done with our patient that had an involvement of cribriform plate and frontal lobe. We also used an adjuvant postoperative radiotherapy with 50-60 Gy resulted in effective local control as indicated by other authors10,27. Furthermore the radiotherapy is recommend for palliative treatment27. The role of systemic chemotherapy in the treatment of ENB has range from no response28-32, palliation20,33, partial14,33-37 and complete response36,38,39. In general chemotherapy is usually reserved for tumor spreading beyond the nasal cavity and paranasal sinuses12, or in the treatment of distant metastases40.
Treatment complications with ENB are high. Visual impairment is the most common adverse effect13, because the location of the tumor is difficult to deliver an adequate dose of radiation without exceeding the tolerance of critical structures such as the brain, optic chiasm and orbits.
The prognostic factors in the management of ENB are very controversy because of the small number of patients presented in each series. Morita1 and Foote41 advocated that the only reliable survival predictor is the tumor's pathological grade (Hyams' grading system42). Polin31 was unable to find significant difference between survival of patients with low and high-grade tumors. Some authors16,43 affirm that the negative prognostic include age, metastasis, recurrence, and extensions to the etmoidal, nasopharyngeal and orbital area. They also noted that the absence of metastasis does not necessarily confer a good prognosis. Goldsweig34 concluded that the degree of resectability of the tumor on primary surgery is the best predictor of long-term survival. Irish determined a 100% 2-year survival rates in patients undergoing combined surgical and radiation treatment. Polin31 informs the 5 and 10 years survival rates of 87 and 54% respectively and a 97% one year survival. Patients with stage C disease have 96% one-year survival, 71% five years and 44% 10 years survival31. In the series of Jekunen40 the median survival time for 11 patients was 27 months, and the median disease-free was 27 months. In the literature the 5-year recurrence free survival is report to be between 52% and 90%16,29,40.
ENB recurs locally in up to 60% of patients who undergo surgery15, and its locally aggressive behavior is the most common cause of death44. Median survival after recurrences was only 12 months45,46. The majority of recurrences occur within the first few years after treatment.
In conclusion, ENB is a very uncommon malignant tumor arising from olfactory epithelium, that have a long natural history characterized by frequent local or regional recurrence. Radical craniofacial resections by a multidisciplinary surgical team combined with adjuvant radiotherapy with 50-60 Gy, is probably the most usual treatment. The role of systemic chemotherapy in the treatment of distant metastasis should be further evaluated.
1. Irish J, Dasgupa R, Freeman J, et al. Outcome and analysis of the surgical management of esthesioneuroblastoa. J Otolaryng 1977;26,:1-7. [ Links ]
2. Berger L, Luc G, Richard D. L' esthesioneuroepitheliome olfactif. Bull Assoc Franç Etude 1924;13:410-421. [ Links ]
3. Stewart F, Frierson H, Levin P, Spaulding C,. Esthesioneuroblastoma. In Williams JG, Krikorian MR, Green D (eds.) Textbook of uncommon cancer. Oxford: Wiley and Sons, 1988:631-652. [ Links ]
4. Broich G, Pagliari A, Ottaviani F. Esthesineuroblastoma: a general review of the cases published since the discovery of the tumour in 1924. Anticancer Res 1997;17:2383-2406. [ Links ]
5. Becker L, Hinton D. Primitive neuroectodermal tumors of the central nervous system. Hum Pathol 1983;14:538-550. [ Links ]
6. Kadish S, Goodman M, Wang C. Olfatory neuroblastoma: a clinical analysis of 17 cases. Cancer 1976;37:1571-1576. [ Links ]
7. Schall L, Lineback M. Primary intranasal neuroblastoma. Ann Otol Rhinol Laryngol 1951;60:221-229. [ Links ]
8. Moore K. The developing human. Philadelphia: Saunders, 1977:174-175. [ Links ]
9. O' Rahilly R, Muller F. The embryonic human brain. New York: Wiley-Liss, 1994:91-337. [ Links ]
10. Elkon D, Hightower S, Meng L. Esthesioneuroblastoma. Cancer 1979; 44:1087-1094. [ Links ]
11. Harrison D. Surgical pathology of olfactory neuroblastoma. Head Neck Surg 1984;7:60-64. [ Links ]
12. Pickuth D, Heywang-Kobrunner H, Spielmann R. Computed tomography and magnetic resonance imaging features of olfactory neuroblastoma: an analysis of 22 cases. Clin Otolaryngol 1999;24:457-461. [ Links ]
13. Simon J, Zhen W, McCulloch T, et al. Esthesioneuroblastoma: The University of Iowa experience 1978-1998. Laringoscope 2001;111:488-493. [ Links ]
14. Morita A, Ebersolod M, Olsen K, Foote R, Lewis J, Quasqst L. Esthesioneuroblastoma: prognosis and management. Neurosurgery 1993;32: 706-715. [ Links ]
15. Biller H, Lawson W, Sachdev V, Som P. Esthesioneuroblastoma: surgical treatment without radiation. Laryngoscope 1990;100:1199-1201. [ Links ]
16. Dulguerov P, Calcaterra T. Esthesioneuroblastoma: the UCLA experience 1970-1990. Laryngoscope 1992;102:843-849. [ Links ]
17. Bastin K, Steeves R, Gilchrist K. Esthesioneuroblastoma: diagnosis, prognosis and treatment. Wis med J 1993;92:17-19. [ Links ]
18. Shaari C, Catalano P, Sen C, Post K. Central nervous system metastases from esthesioneuroblastoma. Otolaryngol Head Neck Surg 1996;114: 808-812. [ Links ]
19. Olsen K, De Santo L. Olfactory neurobllastoma: biologic and clinical behavior. Arch Otolaryngol 1983;109:797-802 [ Links ]
20. Beitler J, Fass D, Brenner H. Esthesioneuroblastoma: is there a role for elective neck treatment. Head Neck 1991;13:321-326. [ Links ]
21. Djalilian M, Zujko R, Weiland D, Devine K. Olfactory neuroblastoma. Surg Clin N Am 1977;57:751-762. [ Links ]
22. Skolnik E, Massari F, Tenta L. Olfactory neuroepithelioma: a review of the world literature and presentation of two cases. Arch Otolaryngol 1966;84:84-93. [ Links ]
23. Parsons J, Mendenhall W, Mancuso A. Malignant tumors of the nasal cavity and ethmoid sinuses. J Radiat Oncol Boil Phys 1988;14:11-22. [ Links ]
24. Cantrell R, Chorayeb B, Fitz-Hugh G. Esthesioneuroblastoma: diagnosis and treatment. Ann Otol Rhinol Laryngol 1977;86:760-765. [ Links ]
25. Oberman H, Rice D. Olfactory neuroblastoma: a clinico-pathologic study. Cancer 1976;38:2494-2502. [ Links ]
26. Doyle P, Payton H. Combined surgical approach to esthesioneuroepithelioma. Trans Pa Acad Ophthalmol Otolaryngol 1971;75:526-531. [ Links ]
27. Eich H, Star S, Mickle O, Eich P, Stutzer H, Muller R. Radiotherapy of esthesioneuroblastoma. Int J Radiation Boil Phys 2001;49:155-160. [ Links ]
28. Sheeran JM, Sheeram JP, Jane J, Polin R. Chemotherapy for esthesioneuroblastomas. Neurosurg Clin N Am 2000;11:693-701. [ Links ]
29. Levine P, Frierson H, Stewart F. Sinonasal undifferentiated carcinoma: a distinctive and highly aggressive neoplasm. Laryngoscope 1987;97: 905-908. [ Links ]
30. Mendeloff J. The olfactory neuroepithelial tumours. Cancer 1957;10:944-956. [ Links ]
31. Polin R, Sheeran J, Chenelle A. The role of pre-operative adjuvant treatment in the management of esthesioneuroblastoma: the University of Virginia experience. Neurosurgery 1998;42:1029-1037. [ Links ]
32. Polonowshi, Brasnu D, Roux F. Esthesioneuroblastoma: a complete tumor response after induction chemotherapy. Ear Nose Throat J 1990; 69:743-746. [ Links ]
33. Tingwald F. Olfactory placode tumors. Laryngoscope 1966;76:196-211. [ Links ]
34. Goldweig H, Sundarsean N. Chemotherapy of recurrent esthesioneuroblastoma: case report review of the literature. Am J Clin Oncol 1990;13: 139-143. [ Links ]
35. Rodas R, Erkman-Balis B, Cahill D. Late intracranial metastasis from esthesioneuroblastoma: a case report and review of the literature. Neurosurgery 1986;9:622-627. [ Links ]
36. Wade P, Smith R, Johns M. Response of esthesioneuroblastoma to chemotherapy. Report of five cases and review of the literature. Cancer 1984;53:1036-1041. [ Links ]
37. Weiden P, Yarington C, Richardson R. Olfactoy neuroblastoma: chemotherapy and radiation for extensive disease. Arch Otolaryngol Head Neck Surg 1984;11:759-760. [ Links ]
38. Grahne B. Olfactory neuroblastoma. Acta Otolaryngol (Stockh) 1965; 59:55-64. [ Links ]
39. Watne K, Hager B. Treatment of recurrence esthesioneuroblastoma with combined intracranial chemotherapy: a case report. J Neurooncol 1987; 5:47-50. [ Links ]
40. Jekunen A, Kalevi J, Kairemo J, Lehtonen H, Kajanti M. Treatment of olfactory neuroblastoma. Am J Clin Oncol 1966;19:375-378. [ Links ]
41. Foote R, Morita A, Ebersold M, et al. Esthesioneuroblastoma: the role of adjuvant radiation therapy. Int J Radiat Oncol Biol 1993;27:835-842. [ Links ]
42. Hyams V, Batsakis J, Michaels L. Olfactory neuroblastoma. In Hyams V, Batsakis J, Michaels L (eds). Tumors of the upper respiratory tract and ear. Washington: Armed Forces Institute of Pathology, 1988:240-248. [ Links ]
43. Homzie M, Elkon D. Olfactory esthesioneuroblastoma: variables predictive of tumors control and recurrence. Cancer 1980; 46:2509-2513. [ Links ]
44. Ahern V, Pousen M. Olfactory neuroblastoma management of a rare tumor at the Queensland Radium Institute and literature review. Australas Radiolol 1991;35:366-369. [ Links ]
45. Eriksen J, Bastholt L, Krogdahi A, Hansen O, Joergesen K. Esthesioneuroblastoma What is the optimal treatment? Acta Oncologica 2000;2:231-235. [ Links ]
46. Tatagiba M, Samii M, Dankoweit-Timpe E, et al. Esthesioneuroblastomas with intracranial extension. Proliferative potencial and management. Arq Neuropsiquiatr 1995;53:577-586. [ Links ]
1Neurocirurgião do Hospital Geral de Fortaleza, Fortaleza CE, Brazil (HGF) e Mestrando em Neurocirurgia da Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo SP, Brazil (UNIFESP-EPM); 2Neurocirurgião do HGF; 3Cirurgião do Setor de Cabeça e Pescoço do HGF; 4Professor Livre-Docente da Disciplina de Neurocirurgia da UNIFESP-EPM.
Received 3 September 2001, received in final form 12 November 2001. Accepted 22 November 2001.
Dr. Jackson Gondim - Rua Dr. Pedro Sampaio 50 - 60181-560 Fortaleza CE - Brasil. E-mail: firstname.lastname@example.org